Alaunos Therapeutics, Inc. financial data

Symbol
TCRT on Nasdaq
Location
2617 Bissonnet St, Suite 233, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 273 % -40.2%
Debt-to-equity 39.1 % +39.7%
Return On Equity -168 % +37.3%
Return On Assets -121 % +42.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.23M shares +39.4%
Common Stock, Shares, Outstanding 2.21M shares +37.8%
Entity Public Float 10.8M USD -88.6%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 2.18M shares +36.3%
Weighted Average Number of Shares Outstanding, Diluted 2.18M shares +36.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7K USD +16.7%
Research and Development Expense 914K USD -33.9%
General and Administrative Expense 3.17M USD -47.6%
Operating Income (Loss) -4.07M USD +66.1%
Nonoperating Income (Expense) 48K USD -78.8%
Net Income (Loss) Attributable to Parent -4.02M USD +65.8%
Earnings Per Share, Basic -2 USD/shares +82.2%
Earnings Per Share, Diluted -2 USD/shares +82.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.94M USD +15.2%
Assets, Current 2.69M USD -24.4%
Property, Plant and Equipment, Net 97K USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 3.72M USD +4.9%
Accounts Payable, Current 843K USD +84.1%
Accrued Liabilities, Current 78K USD -78.8%
Liabilities, Current 921K USD +11.5%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 921K USD +11.5%
Retained Earnings (Accumulated Deficit) -924M USD -0.44%
Stockholders' Equity Attributable to Parent 2.8M USD +2.9%
Liabilities and Equity 3.72M USD +4.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -772K USD +59.7%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 50M shares +900%
Common Stock, Shares, Issued 2.21M shares +37.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -772K USD +59.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.94M USD +15.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 213M USD +1.07%
Deferred Tax Assets, Gross 213M USD +1.07%
Depreciation 2K USD -99.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Property, Plant and Equipment, Gross 15K USD 0%
Operating Lease, Liability, Current 0 USD
Operating Lease, Weighted Average Discount Rate, Percent 0 pure
Deferred Tax Assets, Operating Loss Carryforwards 155M USD +4.48%
Operating Lease, Payments 100K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD -100%